Surface Oncology (Surface Oncology) EBIT per Share : $-1.44 (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology EBIT per Share?

Surface Oncology's EBIT per Share for the three months ended in Jun. 2023 was $-0.41. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.44.

During the past 3 years, the average EBIT per Share Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Surface Oncology's EBIT per Share or its related term are showing as below:

SURF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.4 Med: -30.3 Max: 18.6
Current: 18.6

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Surface Oncology was 18.60% per year. The lowest was -55.40% per year. And the median was -30.30% per year.

SURF's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.5 vs SURF: 18.60

Surface Oncology's EBIT for the three months ended in Jun. 2023 was $-25.08 Mil.

Surface Oncology EBIT per Share Historical Data

The historical data trend for Surface Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology EBIT per Share Chart

Surface Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-0.46

-1.96

1.63

-1.72

-1.08

Surface Oncology Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT per Share	Get a 7-Day Free Trial															-0.45	-0.38	-0.34	-0.31	-0.41

Surface Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Surface Oncology's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-60.44	/	55.761
=	-1.08

Surface Oncology's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.084	/	60.718
=	-0.41

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.44

Surface Oncology (NAS:SURF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Surface Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Surface Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Surface Oncology (Surface Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139

Website

https://www.surfaceoncology.com

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Executives

Chandra Adams	officer: Deputy GC	SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill	officer: Chief Medical Officer
Jessica Fees	officer: See Remarks	C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross	officer: Chief Medical Officer	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath	officer: Chief Business Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella	officer: Chief Scientific Officer	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn	director	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey	director	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater	director, officer: Chief Executive Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p.	10 percent owner	46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc	10 percent owner	56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118